Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved VIRAMUNE opvejede de risici, der er forbundet med stoffet som del af en kombinationsterapi til antiviral behandling af hiv- 1- smittede patienter med fremskreden eller progressiv immuninsufficiens.
The Committee for Medicinal products for Human Use (CHMP) decided that VIRAMUNE’ S benefits are greater than its risks as part of combination therapy for the antiviral treatment of HIV-1 infected patients with advanced or progressive immunodeficiency.